Jan.16, 2020. Phagelux CEO Mark Engel interviewed at JP Morgan Conference. Phagelux looks to raise $20M USD plus, primarily to fund clinical trials. Phagelux clinical programs will uniquely address very large antibiotic resistant pathogen targets.